The Ras-association domain family (RASSF) members and their role in human tumourigenesis

Ras proteins play a direct causal role in human cancer with activating mutations in Ras occurring in ∼ 30% of tumours. Ras effectors also contribute to cancer, as mutations occur in Ras effectors, notably B-Raf and PI3-K, and drugs blocking elements of these pathways are in clinical development. In 2000, a new Ras effector was identified, RAS-association domain family 1 (RASSF1), and expression of the RASSF1A isoform of this gene is silenced in tumours by methylation of its promoter. Since methylation is reversible and demethylating agents are currently being used in clinical trials, detection of RASSF1A silencing by promoter hypermethylation has potential clinical uses in cancer diagnosis, prognosis and treatment. RASSF1A belongs to a new family of RAS effectors, of which there are currently 8 members (RASSF1–8). RASSF1–6 each contain a variable N-terminal segment followed by a Ras-association (RA) domain of the Ral-GDS/AF6 type, and a specialised coiled-coil structure known as a SARAH domain extending to the C-terminus. RASSF7–8 contain an N-terminal RA domain and a variable C-terminus. Members of the RASSF family are thought to function as tumour suppressors by regulating the cell cycle and apoptosis. This review will summarise our current knowledge of each member of the RASSF family and in particular what role they play in tumourigenesis, with a special focus on RASSF1A, whose promoter methylation is one of the most frequent alterations found in human tumours.

[1]  J. Mann,et al.  Frequent epigenetic inactivation of the RASSF1A tumor suppressor gene in Hodgkin's lymphoma , 2004, Oncogene.

[2]  Chun Xing Li,et al.  Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3 , 2000, Nature Genetics.

[3]  J. Minna,et al.  Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. , 2001, Journal of the National Cancer Institute.

[4]  Dominic P. Kwiatkowski,et al.  Haplotype mapping of the bronchiolitis susceptibility locus near IL8 , 2004, Human Genetics.

[5]  L. Hesson,et al.  The RASSF1A Tumor Suppressor Activates Bax via MOAP-1* , 2006, Journal of Biological Chemistry.

[6]  Rong Li,et al.  CpG Island Methylator Phenotype Association with Elevated Serum α-Fetoprotein Level in Hepatocellular Carcinoma , 2007, Clinical Cancer Research.

[7]  K. Bhalla.  Microtubule-targeted anticancer agents and apoptosis , 2003, Oncogene.

[8]  Hiroyuki Yamamoto,et al.  Genetic and epigenetic profiling in early colorectal tumors and prediction of invasive potential in pT1 (early invasive) colorectal cancers. , 2007, Carcinogenesis.

[9]  J. Minna,et al.  The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: identification and evaluation of the resident candidate tumor suppressor genes. The International Lung Cancer Chromosome 3p21.3 Tumor Suppressor Gene Consortium. , 2000, Cancer research.

[10]  S. Thorgeirsson,et al.  Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. , 2006, Gastroenterology.

[11]  Diane D. Liu,et al.  Value of p16INK4a and RASSF1A Promoter Hypermethylation in Prognosis of Patients with Resectable Non–Small Cell Lung Cancer , 2004, Clinical Cancer Research.

[12]  J. Minna,et al.  Allele-specific chromosome 3p deletions occur at an early stage in the pathogenesis of lung carcinoma. , 1995, JAMA.

[13]  G. Pfeifer,et al.  The Tumor Suppressor RASSF1A Does not Interact with Cdc20, an Activator of the Anaphase-Promoting Complex , 2007, Cell cycle.

[14]  A. Bell,et al.  Ras Uses the Novel Tumor Suppressor RASSF1 as an Effector to Mediate Apoptosis* , 2000, The Journal of Biological Chemistry.

[15]  Gangning Liang,et al.  Detection of Methylated Apoptosis-Associated Genes in Urine Sediments of Bladder Cancer Patients , 2004, Clinical Cancer Research.

[16]  C. Larsson,et al.  The t(1;3) breakpoint-spanning genes LSAMP and NORE1 are involved in clear cell renal cell carcinomas. , 2003, Cancer cell.

[17]  J. Avruch,et al.  The putative tumor suppressor RASSF1A homodimerizes and heterodimerizes with the Ras-GTP binding protein Nore1 , 2002, Oncogene.

[18]  Chris P. Ponting,et al.  A novel family ofras-binding domains , 1996 .

[19]  G. Pfeifer,et al.  Epigenetic inactivation of the Ras-association domain family 1 (RASSF1A) gene and its function in human carcinogenesis. , 2003, Histology and histopathology.

[20]  J. Minna,et al.  Progressive aberrant methylation of the RASSF1A gene in simian virus 40 infected human mesothelial cells , 2002, Oncogene.

[21]  A. Chan,et al.  Hypermethylation of the tumor suppressor gene RASSFIA and frequent concomitant loss of heterozygosity at 3p21 in cervical cancers , 2003, International journal of cancer.

[22]  E. Pereira,et al.  Gene expression profiles in human cells submitted to genotoxic stress. , 2003, Mutation research.

[23]  P. Rabbitts,et al.  RASSF1A promoter methylation is frequently detected in both pre‐malignant and non‐malignant microdissected prostatic epithelial tissues , 2007, The Prostate.

[24]  G. Clark,et al.  RASSF2 Is a Novel K-Ras-specific Effector and Potential Tumor Suppressor* , 2003, Journal of Biological Chemistry.

[25]  M. Nistal,et al.  Frequent promoter hypermethylation of RASSF1A and CASP8 in neuroblastoma , 2006, BMC Cancer.

[26]  J. Avruch,et al.  Nore1 inhibits tumor cell growth independent of Ras or the MST1/2 kinases , 2004, Oncogene.

[27]  L. Hesson,et al.  RASSF4/AD037 Is a Potential Ras Effector/Tumor Suppressor of the RASSF Family , 2004, Cancer Research.

[28]  Ishtiaq Rehman,et al.  Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  J. Tangrea,et al.  A survey of gene-specific methylation in human prostate cancer among black and white men. , 2004, Cancer letters.

[30]  A. Protopopov,et al.  The candidate tumor suppressor gene, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[31]  J. Minna,et al.  DNA methylation profiles of lung tumors. , 2001, Molecular cancer therapeutics.

[32]  Yoram Cohen,et al.  Early Occurrence of RASSF1A Hypermethylation and Its Mutual Exclusion with BRAF Mutation in Thyroid Tumorigenesis , 2004, Cancer Research.

[33]  P. Ganly,et al.  p53 and chromosome 3 abnormalities, characteristic of malignant lung tumours, are detectable in preinvasive lesions of the bronchus. , 1992, Oncogene.

[34]  M. Lerman,et al.  Epigenetic inactivation of RASSF1A in head and neck cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[35]  E. Cartwright,et al.  Novel Functional Interaction between the Plasma Membrane Ca2+ Pump 4b and the Proapoptotic Tumor Suppressor Ras-associated Factor 1 (RASSF1)* , 2004, Journal of Biological Chemistry.

[36]  H. Kölbl,et al.  A polymorphism at codon 133 of the tumor suppressor RASSF1A is associated with tumorous alteration of the breast. , 2005, International journal of oncology.

[37]  R. Xavier,et al.  Nore1B regulates TCR signaling via Ras and Carma1. , 2006, Cellular signalling.

[38]  A. Bird,et al.  High levels of De Novo methylation and altered chromatin structure at CpG islands in cell lines , 1990, Cell.

[39]  A. Gazdar,et al.  Hypermethylation of FHIT as a prognostic marker in nonsmall cell lung carcinoma , 2004, Cancer.

[40]  L. Hesson,et al.  RASSF1A Interacts with Microtubule-Associated Proteins and Modulates Microtubule Dynamics , 2004, Cancer Research.

[41]  J. Avruch,et al.  Nore1 and RASSF1 regulation of cell proliferation and of the MST1/2 kinases. , 2006, Methods in enzymology.

[42]  G. Pfeifer,et al.  Frequent hypermethylation of the RASSF1A gene in prostate cancer , 2002, Oncogene.

[43]  W. Kolch.  Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. , 2000, The Biochemical journal.

[44]  J. Minna,et al.  NORE1A, a homologue of RASSF1A tumour suppressor gene is inactivated in human cancers , 2003, Oncogene.

[45]  S. Mohan,et al.  Ras association domain family 1C protein stimulates human lung cancer cell proliferation. , 2006, American journal of physiology. Lung cellular and molecular physiology.

[46]  A. Smith,et al.  Cre-loxP chromosome engineering of a targeted deletion in the mouse corresponding to the 3p21.3 region of homozygous loss in human tumours , 2002, Oncogene.

[47]  S. Nishizuka,et al.  RASSF2, a potential tumour suppressor, is silenced by CpG island hypermethylation in gastric cancer , 2005, British Journal of Cancer.

[48]  R. Yuen,et al.  Hypermethylation of RASSF1A in human and rhesus placentas. , 2007, The American journal of pathology.

[49]  M. Sheikh,et al.  Mitotic kinase Aurora-A phosphorylates RASSF1A and modulates RASSF1A-mediated microtubule interaction and M-phase cell cycle regulation , 2007, Oncogene.

[50]  S. Naylor,et al.  Deletions of the short arm of chromosome 3 in solid tumors and the search for suppressor genes. , 1997, Advances in cancer research.

[51]  G. Clark,et al.  The Pro-apoptotic Ras Effector Nore1 May Serve as a Ras-regulated Tumor Suppressor in the Lung* , 2003, Journal of Biological Chemistry.

[52]  Y. Shim,et al.  Relationship of Ras association domain family 1 methylation and K-ras mutation in primary non-small cell lung cancer. , 2003, Cancer research.

[53]  B. Boehm,et al.  Frequent RASSF1A promoter hypermethylation and K-ras mutations in pancreatic carcinoma , 2003, Oncogene.

[54]  G. Reifenberger,et al.  Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas , 2004, International journal of cancer.

[55]  L. Hesson,et al.  Multigene methylation analysis of Wilms' tumour and adult renal cell carcinoma , 2003, Oncogene.

[56]  B. Neel,et al.  The tumor suppressor RASSF1A and MAP-1 link death receptor signaling to Bax conformational change and cell death. , 2005, Molecular cell.

[57]  G. Pfeifer,et al.  The tumor suppressor RASSF1A in human carcinogenesis: an update. , 2005, Histology and histopathology.

[58]  J. Minna,et al.  Sequential molecular abnormalities are involved in the multistage development of squamous cell lung carcinoma , 1999, Oncogene.

[59]  P. Jackson.  Linking tumor suppression, DNA damage and the anaphase-promoting complex. , 2004, Trends in cell biology.

[60]  K. Katagiri,et al.  Crucial functions of the Rap1 effector molecule RAPL in lymphocyte and dendritic cell trafficking , 2004, Nature Immunology.

[61]  M. Lerman,et al.  Inactivation of RAS association domain family 1A gene in cervical carcinomas and the role of human papillomavirus infection. , 2003, Cancer research.

[62]  Stephen Lam,et al.  Aberrant methylation of multiple genes in the upper aerodigestive tract epithelium of heavy smokers , 2003, International journal of cancer.

[63]  Kohzoh Imai,et al.  The Ras effector RASSF2 is a novel tumor-suppressor gene in human colorectal cancer. , 2005, Gastroenterology.

[64]  M. Widschwendter,et al.  Methylated DNA collected by tampons--a new tool to detect endometrial cancer. , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[65]  J. Minna,et al.  Promoter hypermethylation in benign breast epithelium in relation to predicted breast cancer risk. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[66]  Bertil Johansson,et al.  Genome characteristics of primary carcinomas, local recurrences, carcinomatoses, and liver metastases from colorectal cancer patients , 2004, Molecular Cancer.

[67]  U. Pastorino,et al.  Identification of RASSF8 as a candidate lung tumor suppressor gene , 2006, Oncogene.

[68]  Su Jeong Song,et al.  The Centrosomal Protein RAS Association Domain Family Protein 1A (RASSF1A)-binding Protein 1 Regulates Mitotic Progression by Recruiting RASSF1A to Spindle Poles* , 2005, Journal of Biological Chemistry.

[69]  W. Mckeehan,et al.  Specificity of the methylation-suppressed A isoform of candidate tumor suppressor RASSF1 for microtubule hyperstabilization is determined by cell death inducer C19ORF5. , 2005, Cancer research.

[70]  J. Minna,et al.  Cloning of a breast cancer homozygous deletion junction narrows the region of search for a 3p21.3 tumor suppressor gene , 1998, Oncogene.

[71]  M. Stroun,et al.  Neoplastic characteristics of the DNA found in the plasma of cancer patients. , 1989, Oncology.

[72]  Yucai Wang,et al.  Identification of epigenetic aberrant promoter methylation of RASSF1A in serum DNA and its clinicopathological significance in lung cancer. , 2007, Lung cancer.

[73]  R. Benezra,et al.  Mitotic checkpoints: from yeast to cancer. , 2001, Current opinion in genetics & development.

[74]  R. Schulte‐Hermann,et al.  NORE1B, a candidate tumor suppressor, is epigenetically silenced in human hepatocellular carcinoma. , 2006, Journal of hepatology.

[75]  C. Ricketts,et al.  Transcriptional regulation of cyclin A2 by RASSF1A through the enhanced binding of p120E4F to the cyclin A2 promoter. , 2005, Cancer research.

[76]  Kenichi Harada,et al.  Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines , 2002, Oncogene.

[77]  U. Pastorino,et al.  Common polymorphisms in D12S1034 flanking genes RASSF8 and BHLHB3 are not associated with lung adenocarcinoma risk. , 2007, Lung cancer.

[78]  J. Herman,et al.  K-ras mutations and RASSF1A promoter methylation in colorectal cancer , 2002, Oncogene.

[79]  F. Al-Mulla,et al.  Depletion of the Ras association domain family 1, isoform A-associated novel microtubule-associated protein, C19ORF5/MAP1S, causes mitotic abnormalities. , 2007, Cancer research.

[80]  C. Der,et al.  Analysis of function and regulation of proteins that mediate signal transduction by use of lipid-modified plasma membrane-targeting sequences. , 2000, Methods in enzymology.

[81]  K. Katagiri,et al.  Regulation of immune cell adhesion and migration by regulator of adhesion and cell polarization enriched in lymphoid tissues , 2005, Immunology.

[82]  O. Larsson,et al.  The Ras effectors NORE1A and RASSF1A are frequently inactivated in pheochromocytoma and abdominal paraganglioma. , 2007, Endocrine-related cancer.

[83]  F. Marshall,et al.  High-density mapping of chromosomal arm 1q in renal collecting duct carcinoma: region of minimal deletion at 1q32.1-32.2. , 1996, Cancer research.

[84]  Ishtiaq Rehman,et al.  Molecular Detection of Localized Prostate Cancer Using Quantitative Methylation-Specific PCR on Urinary Cells Obtained Following Prostate Massage , 2007, Clinical Cancer Research.

[85]  H. Kajiho,et al.  Release of RASSF1C from the nucleus by Daxx degradation links DNA damage and SAPK/JNK activation , 2006, The EMBO journal.

[86]  A. Giaccia,et al.  The human Ha-ras oncogene induces genomic instability in murine fibroblasts within one cell cycle. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[87]  D. Kwong,et al.  Evaluation of hypermethylated tumor suppressor genes as tumor markers in mouth and throat rinsing fluid, nasopharyngeal swab and peripheral blood of nasopharygeal carcinoma patient , 2003, International journal of cancer.

[88]  Jane Loveland,et al.  VEGA, the genome browser with a difference , 2005, Briefings Bioinform..

[89]  J. Herman,et al.  RASSF1A methylation and K-ras and B-raf mutations and recurrent endometrial cancer. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[90]  A. V. Starikov,et al.  Extracellular DNA in Breast Cancer: Cell‐Surface‐Bound, Tumor‐Derived Extracellular DNA in Blood of Patients with Breast Cancer and Nonmalignant Tumors , 2004, Annals of the New York Academy of Sciences.

[91]  S. Cross,et al.  Methylational urinalysis: a prospective study of bladder cancer patients and age stratified benign controls , 2006, Oncogene.

[92]  C. Balañà,et al.  Serum DNA as a tool for cancer patient management. , 2003, Roczniki Akademii Medycznej w Bialymstoku.

[93]  S. Lam,et al.  High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints. , 2000, Cancer research.

[94]  G. Clark,et al.  A Role for the RASSF1A Tumor Suppressor in the Regulation of Tubulin Polymerization and Genomic Stability , 2004, Cancer Research.

[95]  D. Morton,et al.  Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients , 2004, Oncogene.

[96]  Y. Shim,et al.  Hypermethylation of RASSF1A promoter is associated with the age at starting smoking and a poor prognosis in primary non-small cell lung cancer. , 2003, Cancer research.

[97]  Seung-Yong Jeong,et al.  Correlation between hypermethylation of the RASSF2A promoter and K‐ras/BRAF mutations in microsatellite‐stable colorectal cancers , 2007, International journal of cancer.

[98]  A. Protopopov,et al.  The RASSF1A tumor suppressor gene is inactivated in prostate tumors and suppresses growth of prostate carcinoma cells. , 2002, Cancer research.

[99]  Su Jeong Song,et al.  The tumour suppressor RASSF1A regulates mitosis by inhibiting the APC–Cdc20 complex , 2004, Nature Cell Biology.

[100]  C. Gerharz,et al.  Methylation Assay for the Diagnosis of Lung Cancer on Bronchial Aspirates: A Cohort Study , 2005, Clinical Cancer Research.

[101]  S. Toyooka,et al.  The relationship between aberrant methylation and survival in non-small-cell lung cancers , 2004, British Journal of Cancer.

[102]  J. Minna,et al.  Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. , 2001, Cancer research.

[103]  J. Kwong,et al.  Aberrant methylation of RASSF4/AD037 in nasopharyngeal carcinoma. , 2004, Oncology reports.

[104]  M. Roncalli,et al.  Quantitative evaluation of RASSF1A methylation in the non-lesional, regenerative and neoplastic liver , 2006, BMC Cancer.

[105]  M. Fraga,et al.  CpG island promoter hypermethylation of the Ras-effector gene NORE1A occurs in the context of a wild-type K-ras in lung cancer , 2004, Oncogene.

[106]  A. Wellmann,et al.  Diagnostic and Prognostic Information in Prostate Cancer with the Help of a Small Set of Hypermethylated Gene Loci , 2005, Clinical Cancer Research.

[107]  A. Newton.  Protein Kinase C: Seeing two domains , 1995, Current Biology.

[108]  F. Gilliland,et al.  Gene Promoter Methylation in Plasma and Sputum Increases with Lung Cancer Risk , 2005, Clinical Cancer Research.

[109]  J. Kwong,et al.  RASSF1A is a target tumor suppressor from 3p21.3 in nasopharyngeal carcinoma , 2004, International journal of cancer.

[110]  Paul Cairns,et al.  Tumor Cell-Specific BRCA1 and RASSF1A Hypermethylation in Serum, Plasma, and Peritoneal Fluid from Ovarian Cancer Patients , 2004, Cancer Research.

[111]  J. Minna,et al.  Identification of the E1A-Regulated Transcription Factor p120E4F as an Interacting Partner of the RASSF1A Candidate Tumor Suppressor Gene , 2004, Cancer Research.

[112]  J. Minna,et al.  Progress in understanding the molecular pathogenesis of human lung cancer. , 1998, Biochimica et biophysica acta.

[113]  Miki Ohira,et al.  Aberrant methylation of RASGRF2 and RASSF1A in human non-small cell lung cancer. , 2006, Oncology reports.

[114]  J. Herman,et al.  Gene silencing in cancer in association with promoter hypermethylation. , 2003, The New England journal of medicine.

[115]  Peter A. Jones,et al.  The Epigenomics of Cancer , 2007, Cell.

[116]  C. Plass,et al.  RASSF1A promoter methylation and Kras2 mutations in non small cell lung cancer. , 2003, Neoplasia.

[117]  J. Minna,et al.  Expression of several genes in the human chromosome 3p21.3 homozygous deletion region by an adenovirus vector results in tumor suppressor activities in vitro and in vivo. , 2002, Cancer research.

[118]  J. Minna,et al.  The Growth and Tumor Suppressor NORE1A Is a Cytoskeletal Protein That Suppresses Growth by Inhibition of the ERK Pathway* , 2006, Journal of Biological Chemistry.

[119]  S. Comincini,et al.  Isolation and molecular characterization of rasfadin, a novel gene in the vicinity of the bovine prion gene , 2001, Mammalian Genome.

[120]  B. Shapiro,et al.  Free DNA in the serum of cancer patients and the effect of therapy. , 1977, Cancer research.

[121]  C. Walczak.  Microtubule dynamics and tubulin interacting proteins. , 2000, Current opinion in cell biology.

[122]  John D Minna,et al.  Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[123]  J. Gillespie,et al.  Heterogeneous gene methylation patterns among pre‐invasive and cancerous lesions of the prostate: A histopathologic study of whole mount prostate specimens , 2004, The Prostate.

[124]  K. Hofmann,et al.  A novel inter action motif, SARAH, connects three classes of tumor suppressor , 2003, Current Biology.

[125]  C. Larsson,et al.  The Ras effector NORE1A is suppressed in follicular thyroid carcinomas with a PAX8-PPARgamma fusion. , 2006, The Journal of clinical endocrinology and metabolism.

[126]  L. Hesson,et al.  RASSF6 is a novel member of the RASSF family of tumor suppressors , 2007, Oncogene.

[127]  Hyeon Joo Lee,et al.  Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia , 2004, The Journal of pathology.

[128]  B. Ng,et al.  The RASSF1A Isoform of RASSF1 Promotes Microtubule Stability and Suppresses Tumorigenesis , 2005, Molecular and Cellular Biology.

[129]  L. Mao,et al.  Promoter methylation of p16INK4a, RASSF1A, and DAPK is frequent in salivary adenoid cystic carcinoma , 2005, Cancer.

[130]  Julian Downward,et al.  Identification of novel gene expression targets for the Ras association domain family 1 (RASSF1A) tumor suppressor gene in non-small cell lung cancer and neuroblastoma. , 2003, Cancer research.

[131]  U. Lehmann,et al.  Quantitative assessment of promoter hypermethylation during breast cancer development. , 2002, The American journal of pathology.

[132]  X. Qian,et al.  RASSF1A and NORE1A methylation and BRAFV600E mutations in thyroid tumors , 2005, Laboratory Investigation.

[133]  G. Pfeifer,et al.  Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma. , 2002, Cancer research.

[134]  R. Uzzo,et al.  Promoter hypermethylation of tumor suppressor genes in urine from kidney cancer patients. , 2003, Cancer research.

[135]  R. Xavier,et al.  Identification of a Novel Ras-Regulated Proapoptotic Pathway , 2002, Current Biology.

[136]  N. Mochizuki,et al.  Local Activation of Rap1 Contributes to Directional Vascular Endothelial Cell Migration Accompanied by Extension of Microtubules on Which RAPL, a Rap1-associating Molecule, Localizes* , 2005, Journal of Biological Chemistry.

[137]  L. Daviet,et al.  RASSF1C, an Isoform of the Tumor Suppressor RASSF1A, Promotes the Accumulation of β-Catenin by Interacting with βTrCP , 2007 .

[138]  Hojoong Kim,et al.  RASSF1A is not appropriate as an early detection marker or a prognostic marker for non‐small cell lung cancer , 2005, International journal of cancer.

[139]  K. Katagiri,et al.  RAPL, a Rap1-binding molecule that mediates Rap1-induced adhesion through spatial regulation of LFA-1 , 2003, Nature Immunology.

[140]  D. Sidransky,et al.  The RASSF1A tumor suppressor gene is commonly inactivated in adenocarcinoma of the uterine cervix. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[141]  S. Tapscott,et al.  De novo methylation of the MyoD1 CpG island during the establishment of immortal cell lines. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[142]  A. Coulson,et al.  Full-genome RNAi profiling of early embryogenesis in Caenorhabditis elegans , 2005, Nature.

[143]  P. Tam,et al.  Ubiquitous Aberrant RASSF1A Promoter Methylation in Childhood Neoplasia1 , 2004, Clinical Cancer Research.

[144]  J. Minna,et al.  Construction of a 600-kilobase cosmid clone contig and generation of a transcriptional map surrounding the lung cancer tumor suppressor gene (TSG) locus on human chromosome 3p21.3: progress toward the isolation of a lung cancer TSG. , 1996, Cancer research.

[145]  J. Avruch,et al.  RASSF3 and NORE1: identification and cloning of two human homologues of the putative tumor suppressor gene RASSF1 , 2002, Oncogene.

[146]  Martin Widschwendter,et al.  Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients. , 2005, Cancer research.

[147]  Chien-Jen Chen,et al.  High frequency of promoter hypermethylation of RASSF1A and p16 and its relationship to aflatoxin B1–DNA adduct levels in human hepatocellular carcinoma , 2002, Molecular carcinogenesis.

[148]  J. Weitzel,et al.  The HRAS1 gene cluster: two upstream regions recognizing transcripts and a third encoding a gene with a leucine zipper domain. , 1992, Genomics.

[149]  J. Avruch,et al.  Regulation of the MST1 kinase by autophosphorylation, by the growth inhibitory proteins, RASSF1 and NORE1, and by Ras. , 2004, The Biochemical journal.

[150]  S. Mohan,et al.  Ras‐Association Domain Family 1 Protein, RASSF1C, Is an IGFBP‐5 Binding Partner and a Potential Regulator of Osteoblast Cell Proliferation , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[151]  L. Hesson,et al.  CpG island promoter hypermethylation of a novel Ras-effector gene RASSF2A is an early event in colon carcinogenesis and correlates inversely with K-ras mutations , 2005, Oncogene.

[152]  Y. Dong,et al.  Systematic functional analysis of the Caenorhabditis elegans genome using RNAi , 2003, Nature.

[153]  M. You,et al.  Tumor susceptibility of Rassf1a knockout mice. , 2005, Cancer research.

[154]  W. V. D. Van de Ven,et al.  The fibulin-1 gene (FBLN1) is disrupted in a t(12;22) associated with a complex type of synpolydactyly , 2002, Journal of medical genetics.

[155]  E. Máthé.  RASSF1A, the new guardian of mitosis , 2004, Nature Genetics.

[156]  E. Maher,et al.  Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients , 2003, Oncogene.

[157]  Christina Kiel,et al.  Recognizing and defining true Ras binding domains I: biochemical analysis. , 2005, Journal of molecular biology.

[158]  S. Barik,et al.  Activation of cytokines and NF-kappa B in corneal epithelial cells infected by respiratory syncytial virus: potential relevance in ocular inflammation and respiratory infection , 2004, BMC Microbiology.

[159]  A. Chan,et al.  Frequent hypermethylation of promoter region of RASSF1A in tumor tissues and voided urine of urinary bladder cancer patients , 2003, International journal of cancer.

[160]  S. Toyooka,et al.  Aberrant promoter methylation in pleural fluid DNA for diagnosis of malignant pleural effusion , 2007, International journal of cancer.

[161]  Daiya Takai,et al.  The CpG Island Searcher: A new WWW resource , 2003, Silico Biol..

[162]  J. Fagin,et al.  The RAS oncogene induces genomic instability in thyroid PCCL3 cells via the MAPK pathway , 2000, Oncogene.

[163]  Y. Tomizawa,et al.  Epigenetic inactivation of the RAS-effector gene RASSF2 in lung cancers. , 2007, International journal of oncology.

[164]  K. Katagiri,et al.  Spatiotemporal regulation of the kinase Mst1 by binding protein RAPL is critical for lymphocyte polarity and adhesion , 2006, Nature Immunology.

[165]  D. Lim,et al.  Control of APC-Cdc20 by the Tumor Suppressor RASSF1A , 2004, Cell cycle.

[166]  E. Sauter,et al.  Detection of Breast Cancer in Nipple Aspirate Fluid by CpG Island Hypermethylation , 2004, Clinical Cancer Research.

[167]  M. Hoque,et al.  A Quantitative Promoter Methylation Profile of Prostate Cancer , 2004, Clinical Cancer Research.

[168]  Paul Cairns,et al.  Tumor Suppressor Gene Promoter Hypermethylation in Serum of Breast Cancer Patients , 2004, Clinical Cancer Research.

[169]  M. Sheikh,et al.  Tumor suppressor RASSF1A is a microtubule-binding protein that stabilizes microtubules and induces G2/M arrest , 2004, Oncogene.

[170]  J. Minna,et al.  Inactivation of RASSF1C during in vivo tumor growth identifies it as a tumor suppressor gene , 2004, Oncogene.

[171]  Zhe Zhang,et al.  Inactivation of RASSF2A by promoter methylation correlates with lymph node metastasis in nasopharyngeal carcinoma , 2007, International journal of cancer.

[172]  N. Park,et al.  Association of promoter hypermethylation of the RASSF1A gene with prognostic parameters in endometrial cancer. , 2006, Oncology research.

[173]  S. T. Kim,et al.  Substrate Specificities and Identification of Putative Substrates of ATM Kinase Family Members* , 1999, The Journal of Biological Chemistry.

[174]  J. Minna,et al.  Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours , 2001, Oncogene.

[175]  M. Rhyu,et al.  Epstein-barr virus-positive gastric carcinoma demonstrates frequent aberrant methylation of multiple genes and constitutes CpG island methylator phenotype-positive gastric carcinoma. , 2002, The American journal of pathology.

[176]  S. Cross,et al.  Evidence for the early onset of aberrant promoter methylation in urothelial carcinoma , 2006, The Journal of pathology.

[177]  Jeanne Kowalski,et al.  Hypermethylation of CpG Islands in Primary and Metastatic Human Prostate Cancer , 2004, Cancer Research.

[178]  Joost Schymkowitz,et al.  Recognizing and defining true Ras binding domains II: in silico prediction based on homology modelling and energy calculations. , 2005, Journal of molecular biology.

[179]  J Downward,et al.  Ras signalling and apoptosis. , 1998, Current opinion in genetics & development.

[180]  Y. Yatabe,et al.  RASSF1A gene inactivation in non‐small cell lung cancer and its clinical implication , 2003, International journal of cancer.

[181]  K. Kaibuchi,et al.  Ras-induced transformation and signaling pathway. , 1999, Journal of biochemistry.

[182]  J. Minna,et al.  Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[183]  Z. Qian,et al.  Inactivation of RASSF1A tumor suppressor gene by aberrant promoter hypermethylation in human pituitary adenomas , 2005, Laboratory Investigation.

[184]  Tsung-Teh Wu,et al.  Epigenetic alterations in neuroendocrine tumors: methylation of RAS-association domain family 1, isoform A and p16 genes are associated with metastasis , 2005, Modern Pathology.

[185]  P. Güntert,et al.  Structural insight into dimeric interaction of the SARAH domains from Mst1 and RASSF family proteins in the apoptosis pathway , 2007, Proceedings of the National Academy of Sciences.

[186]  J. Minna,et al.  The RASSF1A Tumor Suppressor Blocks Cell Cycle Progression and Inhibits Cyclin D1 Accumulation , 2002, Molecular and Cellular Biology.

[187]  Amos Bairoch,et al.  The PROSITE database , 2005, Nucleic Acids Res..

[188]  J. Herman,et al.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[189]  Y. Yoo,et al.  RASSF1A suppresses the c-Jun-NH2-kinase pathway and inhibits cell cycle progression. , 2005, Cancer research.

[190]  W. Mckeehan,et al.  Novel complex integrating mitochondria and the microtubular cytoskeleton with chromosome remodeling and tumor suppressor rassf1 deduced by in silico homology analysis, interaction cloning in yeast, and colocalization in cultured cells , 2002, In Vitro Cellular & Developmental Biology - Animal.

[191]  N. Tapon,et al.  The Drosophila RASSF Homolog Antagonizes the Hippo Pathway , 2006, Current Biology.

[192]  K. Hoang-Xuan,et al.  Frequent epigenetic inactivation of RASSF1A and BLU genes located within the critical 3p21.3 region in gliomas , 2004, Oncogene.

[193]  J. Kwong,et al.  High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma. , 2001, Cancer research.

[194]  Hong Zhou,et al.  Involvement of Ras Activation in Human Breast Cancer Cell Signaling, Invasion, and Anoikis , 2004, Cancer Research.

[195]  G. Pfeifer,et al.  Control of microtubule stability by the RASSF1A tumor suppressor , 2003, Oncogene.

[196]  L. Hesson,et al.  The Role of RASSF1A Methylation in Cancer , 2007, Disease markers.

[197]  R. Uzzo,et al.  Detection of Bladder Cancer in Urine by a Tumor Suppressor Gene Hypermethylation Panel , 2004, Clinical Cancer Research.

[198]  Y. Hata,et al.  Ras-association domain family protein 6 induces apoptosis via both caspase-dependent and caspase-independent pathways. , 2007, Experimental cell research.

[199]  C. Moon,et al.  Detection of Promoter Hypermethylation of Multiple Genes in the Tumor and Bronchoalveolar Lavage of Patients with Lung Cancer , 2004, Clinical Cancer Research.

[200]  M. Widschwendter,et al.  DNA methylation in serum of breast cancer patients: an independent prognostic marker. , 2003, Cancer research.

[201]  C. Marsit,et al.  Carcinogen Exposure and Epigenetic Silencing in Bladder Cancer , 2006, Annals of the New York Academy of Sciences.

[202]  Kornelia Polyak,et al.  Very High Frequency of Hypermethylated Genes in Breast Cancer Metastasis to the Bone, Brain, and Lung , 2004, Clinical Cancer Research.

[203]  S. Chi,et al.  Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma. , 2001, Cancer research.

[204]  G. Pfeifer,et al.  RASSF1A Is Part of a Complex Similar to the Drosophila Hippo/Salvador/Lats Tumor-Suppressor Network , 2007, Current Biology.

[205]  J. Avruch,et al.  Identification of Nore1 as a Potential Ras Effector* , 1998, The Journal of Biological Chemistry.

[206]  G. Pfeifer,et al.  Involvement of the RASSF1A tumor suppressor gene in controlling cell migration. , 2005, Cancer research.

[207]  C. Eng,et al.  RASSF1A promoter region CpG island hypermethylation in phaeochromocytomas and neuroblastoma tumours , 2001, Oncogene.

[208]  S. Chi,et al.  Frequent epigenetic inactivation of RASSF1A by aberrant promoter hypermethylation in human gastric adenocarcinoma. , 2001, Cancer research.

[209]  R. Xavier,et al.  The Scaffold Protein CNK1 Interacts with the Tumor Suppressor RASSF1A and Augments RASSF1A-induced Cell Death* , 2004, Journal of Biological Chemistry.